As a sponsor for the third annual OneMedForum New York to be held July 11-12, BDO Life Sciences will host a special workshop to discuss compensation practices at life sciences companies.
As the US begins to see more and more soldiers return home from combat after the last decade of wars, finding a viable treatment for PTSD should and will be a more prominent concern in the minds of many.
OneMedForum New York 2012 will offer a diagnostics panel session on the afternoon of July 12th to discuss the rapid technological advances in diagnostics and personalized medicine.
Frank Reynolds, of InVivo Therapeutics (NVIV), says the company is on the verge of unprecedented technology for the treatment of the spinal cord.
Zymeworks Inc. is a privately held biotechnology company committed to developing best-in-class protein therapeutics for the treatment of cancer.
The Greater Zurich Area AG is responsible for promoting and marketing one of the world’s leading Life Sciences and MedTech hubs.
According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
OncoSec Medical is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease.
OneMedPlace held a 2nd reception to promote OneMedForum New York 2012 last Thursday at The Chasson Group offices.
New “rinse and spit” screen for oral cancer could reduce disfigurement and save lives. Vigilant Biosciences, Inc., recently announced the appointment of David Barshis as Chief Executive Officer.
Copyright © 2025 | WordPress Theme by MH Themes